Preliminary Programme 2018
Thursday, December 6
* Competing for the MAC Award
09.00-10.35 | CAR 1: Clinical and imaging variables in asymptomatic carotid patients with an increased stroke risk - critical revision of the ESVS/ESC GL 2017 |
| Barbara Rantner | Clinical variables with an increased late stroke risk |
| David Spence | Spontaneous embolisation on TCD and carotid plaque features |
| Peter Ringleb | Silent infarction and impaired cerebrovascular reactivity |
| Kosmas Paraskevas | Grade of carotid stenosis and stenosis progression |
| Jonathan Nadjiri | MRI features of unstable carotid plaques |
| Jens Göttler | Multi-modal MRI identifies carotid patients with reduced cerebral blood flow and oxidative metabolism |
| Alison Halliday | Keynote Lecture: How to select asymptomatic carotid patients for CEA (or CAS) BMT plus - a critical review of the ESVS/ESC guidelines |
11.00-12.45 | CAR 2: More news on carotid revascularization stratgies and long-term outcomes in (a)symptomatic carotid patients |
| Ralf Kolvenbach | Transcarotid stenting with flow reversal: does the kind of stent matter? |
| Klaus Matthias | Early and one year data from the Scaffold (micromesh) CAS Trial |
| Sumaira MacDonald | Control of the microembolic burden of the carotid bifurcation lesion: comparison of various endovascular strategies |
| Christos Liapis | Total occlusion of the internal carotid artery - not a benign condition |
| Kosmas Paraskevas | Outcomes following eversion vs. conventional CEA in RCTs and observational studies - a systematic review |
| Armelle Meershoek* | Long term outcomes of symptomatic patients undergoing hybrid revascularization for extracranial carotid artery tandem stenosis |
| Marc Schermerhorn | Keynote lecture: Transcarotid stenting (T-CAR) versus CEA and transfemoral CAS in the SVS Vascular Quality Initiative (VQI, USA) |
| Hans Förstl | Special Lecture 1: Cognitive impairment and dementia in politicians |
13.30-15.00 | CAR 3: Prospective meta-analyses of individual patient data from investigator-initiated RCTs (SPACE, CREST, ACST, ICSS, EVA3-S, GALA) |
| Tilman Reiff | Stroke and TIA rates at one year in SPACE-2: BMT versus CEA versus CAS in asymptomatic carotid stenosis |
| Richard Bulbulia | Current status and perspectives of ACST-2, CREST-2, and ECST-2 |
| Gert de Borst | Safety of carotid revascularization in patients with a history of coronary heart disease |
| Christof Knappich | Perioperative and clinical variables affecting the 30-day risk of stroke or death after symptomatic CEA |
| Dylan Morris | Risk factors for major operative complications following asymptomatic CEA - 4.440 CEA from VACS, ACAS, ACST-1 and the GALA trial |
| Evelien de Vries* | Carotid stent failure as a predictor for periprocedural stroke or death after CAS - a substudy from ICSS |
| Leo Bonati | Keynote Lecture: Immediate, intermediate, and long-term results after CEA and CAS in four RCTs on symptomatic carotid stenosis |
15.00-16.00 | CAR 4: Short communications on Carotid Diseases |
| Klaus Matthias | Carotid artery aneurysms - what endovascular treatment can achieve |
| Vanessa Pourier | Gadolinium enhancement and white matter lesions in extracranial carotid artery aneurysms |
| Astrid Hoving | The performance of ultrasound particle image velocimetry in a carotid artery phantom with stent |
| Christoph Schäffer | Non-invasive assessment of carotid plaque burden with tomographic ultrasound |
| Armelle Meershoek | Treatment of internal carotid artery NEar occlusiON (NEON study): An individual patient data meta-analysis |
| Ihor Kobza | The choice of the optimal method of surgical correction of atherosclerotic carotid lesions |
| Peter Konstantiniuk | The ASA classification predicts the ipsilateral stroke free survival in asymptomatic octogenarians with elective CEA |
| Evelien de Vries | Standardization of semiautomatic tortuosity measurements in the carotid artery |
| Leonie Fassaert | Defining the awake blood pressure in patients undergoing CEA |
| Pedro Pinto Sousa | Moderate (50-69%) symptomatic carotis stenosis - what should we do? |
* Competing for the MAC Award
09.00-10.30 | AOR 1: Short communications on Aortic Diseases |
| Ahmed Eleshra | Different zones (0-2) of hybrid de-branching endovascular aortic repair: outcomes and stroke analysis |
| Mikhail Chernyavskiy | Mid-term results of hybrid aortic arch repair |
| Pedro Pinto Sousa | Acute aortic syndrome - three typical case presentations |
| Arnaud Kerzmann | Results of left subclavian artery revascularization prior to elective TEVAR |
| Ahmad Naga | Combined TEVAR and EVAR to treat thoracic type IB endoleak and infrarenal AAA |
| Rita Augusto | Late Type 1a endoleak after EVAS: a unique challenge |
| Sigitas Urbonavicius | Urine biomarkers for AAA rupture - is it possible? |
| Albert Busch | Angiogenese-inhibition and AAA |
| Liu Shengliang | Role of neutrophil extracellular traps in AAA disease development and progression |
| Jasamin Coles-Black | An easily reproducable 3D printed AAA model using open source digital tools |
| Pedro Pinto Sousa | Endovascular aneurysm repair in octogenarians |
| Jacinta Campos | Mycotic aortic aneurysm secondary to intravesical BCG instillation - is an endovascular approach an effective solution? |
| Makhmud Akhmad | Endovascular diagnostics and treatment of acute abdominal bleedings after hepato-pancreatico-duodenal surgery |
| Matthias Trenner | Impact of the patient risk on the volume-outcome effect for AAA surgery |
| Stefan Ockert | Short Report: endovascular one stop shopping: EVAR + TAVI |
| Lars Lönn | Computer-controlled aortic occlusion (REBOA) for the treatment of cardiac arrest and bleedings |
11.00-12.35 | AOR 2: Dismantling AAAs - novel insights into disease mechanisms and future therapies |
| Andrew Baker | Exploiting novel targets in vascular remodeling and disease formation |
| Anders Wanhainen | Update on non-invasive treatments for AAA disease |
| Rebecka Hultgren | Gender aspects in AAA disease |
| Joy Roy | Biomechanical modeling of AAA growth and rupture; a clinical perspective |
| Wolf Eilenberg* | The association of neutrophil activation markers with morphological features of AAA |
| Markus Wagenhäuser* | Nicotine is a regulator of segmental aortic stiffening - Implications for AAA development |
| Valentina Paloschi* | Aorta-on-a-chip: a novel tool to gain molecular insights into aneurym disease |
13.30-14.45 | AOR 3: Biomechanics and simulation of aortic aneurysms |
| T. Christian Gasser | Predicting three-dimensional AAA growth from CT-A images |
| Stephane Avril | Patient-specific numerical simulation of endovascular aneurysm repair |
| Michael Gee | In Silico EVAR for Abdominal Aortic Aneurysms |
| Tina Cohnert | Advances in biomechanic and structural AAA wall analysis |
| Benedikt Reutersberg | The SCAN study reveals, that cardiovascular patients should always be screened for AAA |
* Competing for the MAC Award
15.30-17.00 | PAD 1: Innovative imaging and below-the-knee treatment modalities |
| Jean-Paul de Vries | DETECT-PAD II: computerized and patient specific model to determine pressure gradients in borderline stenosis with MRA / CTA. |
| Jos van den Berg | Zero contrast procedure by use of unenhanced MRA and CO2 angiography |
| Michael Rasper | 3D non-contrast-enhanced ECG-gated MR angiography of the lower extremities |
| Jean-Paul de Vries | The REPEAT study: validation of perfusion angiography measurements for below-the-knee arteries in CLI patients |
| Marianne Brodmann | Early results from a RCT on below-the-knee drug-eluting balloons |
| Peter Goverde | One year results of real-life use of the latest generation of balloon expandable DES in below-the-knee treatment |
| Achim Neufang | Surgical arterialisation of the plantar venous system for foot salvage after failed endovascular or operative revascularisation |
17.20-18.35 | PAD 2: Peripheral and mesenteric vascular emergencies |
| Anders Wanhainen | Open or endovascular revascularization in the treatment of acute lower limb ischaemia |
| Kerstin Stoklasa | Outcomes of a consecutive series of 708 patients with acute limb ischaemia |
| Heli Järve* | Acute mesenteric ischaemia: irreversible versus reversible bowel damage - a single centre experience |
| Suzanne Evans* | Mesenteric vascular injuries in trauma: a National Trauma Data Bank (NTDB) study from the US |
| Adel Kamhawy | Arterial injury associated with pediatric supracondylar humerus fracture - exploration or observation? |
| Ralf Kolvenbach | Keynote Lecture: Civilian and pediatric vascular trauma management - an overview |
17.30-18.40 | SPECIAL SESSION 1: Hot topics in radiation protection 2018 |
| Tina Cohnert | Advanced radiation protection in the Hybrid OR with Zero Gravity |
| Stefan Ockert | Radiation exposure during C-arm supported EVAR with the Siemens Pheno system |
| Bijan Modarai | Risks associated with protracted low dose radiation exposure |
| Dittmar Böckler | Evidence of radiation induced cataracts and brain tumors |
| Stefan Ockert | EVAS might be associated with a decrease in intraoperative radiation dose as compared to EVAR |
Friday, December 7
* Competing for the MAC Award
08.30-10.00 | CAR 5: Carotid artery disease - from genes to therapies |
| Martin Dichgans | Stroke Genetics: discovery, biology, and clinical implications |
| Jan Nilsson | Factors associated with progression of carotid disease in high risk patients |
| Thorsten Kessler | Implementing genetics into clinical practice in cardiovascular disease management |
| Judith Sluimer | Interplay of oxygen sensors, inflammation and cholesterol metabolism in atherosclerosis |
| Hanna Winter* | Long non-coding RNA NUDT6 regulates fibrous cap thickness in advanced atherosclerosis |
| Joachim Schmidt* | Expression of human somatostatin receptors and glucose transporters in carotid artery stenosis and aneurysms |
10.30-11.30 | CAR 6: Carotid ultrasound session on carotid plaque burden and plaque vulnerability |
| David Spence | Keynote Lecture: Carotid plaque burden predicts future cardiovascular events - why and how I do it! |
| Steven Rogers | Will carotid plaque volume assessed by 3D tomographic ultrasound be an altenative indicator for CEA or CAS? |
| Holger Poppert | How to detect and to stratify DUS findings at the carotid bifurcation (echolucency, ulceration, etc.) |
| Marjolijn Rots* | Correlation between plaque characteristics and presence of preoperative white matter lesions in patients undergoing CEA |
| Igor Koncar | TAXINOMISIS - a multidisciplinary EU project on stratification of patients with carotid artery disease |
* Competing for the MAC Award
10.30-12.10 | AOR 4: Ascending aorta and aortic arch |
| Jes S Lindholt | DANCAVAS trial: the incidence of coexisting aortic aneurysms and why ascending AA might be overdiagnosed! |
| Martin Czerny | The EACTS/ESVS expert consensus document for the treatment of thoracic aortic pathologies affecting the aortic arch |
| Ralf Kolvenbach | Status of ascending aortic stent grafts in true aneurysms |
| Martin Czerny | Total endovascular treatment of aortic arch pathologies using branched endografts |
| Ali Shahriari | Repair of acute DeBakey I dissections using a novel dissection- specific arch hybrid graft (AMDS) |
| Celia Riga | Contact force assessment in the arch during TEVAR: How do different graft designs perform? |
| Jonathan Nadjiri | Assessment of flow-displacement und wall-shear-stress by 4-D aortic MR-Angiography - new options as compared to CTA |
| Julian Scott | SPECIAL LECTURE 2: Sarcopenia and outcomes in Vascular Surgery |
13.00-14.40 | AOR 5: Thoracic/Thoraco-abdominal aneurysm and dissections |
| Dittmar Böckler | Prevalence of the computed tomographic morphological DISSECT predictors in uncomplicated Stanford Type B aortic dissection |
| Igor Koncar | Early TEVAR in acute type B dissection |
| Bijan Modarai | Contemporary treatment of type B aortic dissection: Is there a need for a disease specific approach to endografting? |
| Eric Verhoeven | Treatment of chronic aortic dissections with fenestrated and branched endografts |
| Celia Riga | Frozen elephant trunk techniques for chronic Type B dissections |
| Athanasios Katsargyris | Inner branches as an additional option besides fenestrations and branches in TAAA branched grafting |
| Colin Bicknell | Prevention and revision of TEVAR utilising EndoAnchors to reduce and treat endoleak |
| Sebastian Debus | The SPIDERgraft: can this novel technique decrease complications after thoracoabdominal repair? |
| Christos Liapis | Side effects of EVAR and EVAR on the heart - myth or reality? |
15.05-16.40 | AOR 6: A critical revision of the new AAA guidelines from the ESVS, SVS and the German Vascular Society (DGG), and NICE (UK)I |
| Anders Wanhainen | Keynote Lecture: The new AAA guidelines from the ESVS – what is new and what is different from the 2017 SVS AAA guidelines? |
| Sebastian Debus | Are there any different recommendations in the 2018 AAA guidelines from the German Vascular Society (DGG)? |
| Mike Wyatt | Changes to the management of patients with AAA in the UK: Is NICE out of touch with worldwide best practice? |
| Athanasios Giannoukas | Some small AAAs (4.5-5.5 cm) should be treated - How to select them? |
| Thomas Schmitz-Rixen | How valid is the diameter threshold of 5/5,5 cm for repair and do we need new RCTs to further improve our AAA management? |
| Jes S Lindholt | Do we need another RCT for AAA 5-5.5 or 5.5-6.0 cm? |
| Clark Zeebregts | Accuracy of routine endoscopy diagnosing colonic ischaemia after abdominal aortic aneurysm repair: a meta-analysis. |
| Igor Koncar | Morphological predictors of an increased AAA rupture risk |
| Rachael Forsythe | Multi-modality molecular and cellular imaging to predict AAA disease progression: towards personalised assessment of disease |
17.00-18.30 | AOR 7: Complex AAA and endoleak management |
| Christian Reeps | Role of aortic surgery in radical cancer resection |
| Lars Lönn | Qualitative review of studies reporting on re-interventions after elective EVAR - a systematic review |
| Marc Schermerhorn | Selected Type I and III EL at completion of FEVAR are safe to observe |
| Colin Bicknell | Endovascular strategies for treatment of type I EL in EVAR |
| Albert Busch | Expansion and atrophy - aortic wall development after EVAR with endoleak type II |
| Jean-Paul de Vries | Determinants of successful and unsuccessful deployment of EndoAnchors in hostile necks; evaluation of >300 implants |
| Matthias Trenner | Intraarterial CEUS - first experience with a new technique to detect early endoleaks in EVAR |
| Clark Zeebregts | The GLOBAL FACT Registry: a world-wide registry with core lab analysis of fenestrated Anaconda for complex aortic aneurysms |
| Alexander Oberhuber | The (JOTEC®) iliAc BRAnch device for exclusion of Hypogastric Artery aneurysMs - ABRAHAM trial |
* Competing for the MAC Award
08:30-10:10 | PAD 3: Challenges in PAD: long and calcified femoro-popliteal lesions, in-stent-restenosis (ISR), and wound healing |
| Peter Goverde | New DAWN - one year results combining Supera VMI and DCB for the treatment of long femoro-popliteal lesions |
| Jean-Paul de Vries | 2 years results of the RAPID trial - RCT comparing Legflow DCB with Supera stenting vs. Supera alone for SFA lesions |
| Thomas Zeller | Are there any differences between different drug-eluting stents for femoro-popliteal lesions |
| Alexander Zimmermann | The SVS objective performance goals (OPG) are achievable for surgical therapy in a consecutive CLI all-comers cohort |
| Gunnar Tepe | 2 years results of the COPA CABANA RCT of DCB versus PTA for femoro-popliteal in-stent-restenosis |
| Jos van den Berg | Current status of in-stent-restenosis treatment in the SFA |
| Peter Goverde | Flow dynamics and patency rates indicate superiority of covered over kissing aortic bifurcation stents |
| Alexander Gombert* | Closed-incision negative-pressure therapy reduces vascular surgical site infections: a prospective RCT (AIMS trial) |
| George Geroulakos | Time of complete healing of leg ulcers following revascularization for critical limb ischaemia |
14.30-15.35 | PAD 4: Update on lipid-lowering therapy in peripheral atherosclerosis |
| David Spence | Best medical treatment for asymptomatic carotid disease - optimal LDL levels are achievable! |
| Richard Bulbulia | Intensive lipid-lowering for plaque stabilisation and regression? Implications for surgeons and our patients! |
| Barbara Rantner | Cardiovascular morbidity and mortality in patients with intermittent claudication - medical long-term intervention is a MUST |
| Mark Schermerhorn | Survival after lower extremity revascularization for critical limb-threatening ischaemia (CLTI) is better with high-dose statin |
| NN | PCSK9 inhibitor evolocumab in patients with and without PAD |
15.35-16.30 | PAD 5: Update on periprocedural and long-term platelet inhibition and anticoagulation in PAD |
| Christine Espinola-Klein | Update on periprocedural and long-term antithrombotic management in PAD |
| Michael Spannagl | How to assess and individualize platelet inhibition in PAD |
| Thomas Stadlbauer | Platelet inhibition PLUS low-dose anticoagulation - a new paradigm for all PAD patients? |
| NN | PAD and atrial fibrillation - how to balance out anticoagulation and antithrombotic treatment |
17.00-18.00 | PAD 6: Short communications on Peripheral Arterial Disease (PAD) |
| Dmitry Dombrovskyi | Transplantation of stem cells of different origin for the treatment of lower limb ischaemia |
| Chiara Mozzini | Cardiovascular diseases: focus on endoplasmatic reticulum stressand NRF2 signalling |
| Akshitha Kesharaju | Sarcopenia as predictor of mortality and morbidity following major lower limb amputation |
| Mohamed Nagib | Transbrachial approach as an alternative method in the management of aortoilliac occlusive arterial diseases. |
| Sabine Dallmann-Sieber | Acute occlusions of the infrarenal aorta - single-center experience of 68 patients in a 14-year-period |
| Bianca Marinelli Teixeira | Rare atherosclerotic aneurysms of the dorsalis pedis artery in young women - case reports and literature review |
| Sohiel Nagib | Cost effectiveness of Carbon Dioxide as Contrast Medium for the Endovascular treatment of PAOD in patients with renal dysfunction |
| Yuriy Levchak | Adventitial cystic disease of the lower extremities main vessels |
| Emad Hussein | Infragenicular PAOD in south mediterranean patients - towards a sound endovascular strategy |
12.00-13.00 | VEN 1: Venous Challenge - successful strategies to treat venous lesions (Industry-Sponsored) |
| Tobias Steinke | The endovascular option for AV-fistula creation |
| Tobias Steinke | How to treat the AV-Fistula stenosis best |
| Houman Jalaie | The right way to treat chronic venous lesions - Tips and tricks in diagnostic, indication, and treatment |
| Nils Kucher | What we learned from the „Attract“-Study |
12.30-14.00 | SPECIAL SESSION 2: Team training |
| Markus Kleemann | Augmented reality for navigated EVAR |
| Mark Kaschwich | A modular approach for an endovascular training environment using rapid prototyping as part of the Nav-EVAR project |
| Lars Lönn | Metric-based virtual reality simulation - a paradigm shift in training for severe stroke |
| Celia Riga | An optimised team training for EVAR & TEVAR - how do you set it up and what is the evidence? |
| Dittmar Böckler | How to train the surgical staff in the hybrid OR in radiation protection |
| Heiko Wendorff | Mid-term effects of an Intensive radiation-protection-Training on the Intraoperative radiation exposure in the Hybrid OR |
Saturday, December 8
09.00-09.55 | VEN 2: Short communications on Venous Diseases |
| Luís Gamas | Venous stenting: initial experience and follow up in a Portuguese center |
| Mohamed Nagib | Laser crossectomy versus anterior accessory saphenous vein laser ablation in treating the anterior accessory saphenous vein reflux |
| Sohiel Nagib | Acute upper extremity deep vein thrombosis (DVT) - indications and effectiveness of superior caval filters |
| Mohamed Ismail | Role of Inferior vena cava filter insertion prior to thrombolysis of acute ilio femoral deep venous thrombosis |
| Mangesh Tarte | Inferior caval obstruction - limited role of endovenous therapy |
| Andrij Nykonenko | Diagnostic management of the „nutcracker syndrome“ |
| Larysa Chernukha | Management of the pelvic congestion synsdrome |
| Olena Kashyrova | Modern approaches in the treatment of diffuse forms of extremity congenital vascular malformations with the presence of microfistulas |
| Mangesh Tarte | Combined role of Laser ablation, Ethanol embolisation, and foam sclerotherapy in the treatment of venous malformations |
| Adel Kamhawy | Surgical management of high and low-flow vascular malformations |
09.55-11.00 | VEN 3: Deep vein thrombosis (DVT) - conservative and recanalizing strategies |
| Armando Mansilha | Treating acute DVT with DOACs - advances and challenges |
| Andrij Nykonenko | Surgical versus conservative treatment of deep venous thrombosis: follow-up and quality of life |
| Stefan Ockert | Quality of life and post-thrombotic syndrome after surgical thrombectomy of acute iliofemoral DVT |
| George Geroulakos | Complications of endovascular treatment for the management of May-Thurner syndrome |
| Alun Davies (tbc) | Antithrombotic therapy following venous stenting: International Delphi Consensus |
11.30-13.00 | VEN 4: New developments in lower leg varicosis |
| Sigitas Urbonavicius | A novel view at the pathogenesis of varicose veins: proteomic analysis |
| Thomas Hirsch | Interventional treatment of perforator veins |
| Jan Beyer-Westendorf | Thromboembolic complications in superficial-vein thrombosis under Rivaroxaban or Fondaparinux: the randomised SURPRISE trial |
| NN | High ligation and crossectomy are still an option in superficial-vein thrombosis close to the sapheno-femoral junction |
| Alun Davies (tbc) | Keynote Lecture: EVRA - a randomized trial of early endovenous ablation in venous ulceration |
| Thomas Pröbstle | Current status of non-termal/non-tumescent saphenous ablation |
| Thomas Hirsch | What do we know about the allergenic risk of adhesive vein treatments? |
13.30-15.00 | VEN 5: Current guidelines on chronic venous diseases - a critical overview |
| Armando Mansilha | Keynote lecture: why the current international guidelines are not always accurate to define the best technique for varicose veins |
| Alun Davies (tbc) | Strengths and weakpoints of the 2017 ESVS guideline on chronic venous diseases |
| Mike Wyatt | Multimodal treatment of small saphenous vein reflux |
| NN | Multimodal treatment of greater saphenous vein reflux |
| NN | Periprocedural and long-term compression therapy - indications, evidence, and outcomes |
| Houman Jalaie | The postthrombotic syndrome - prevention and recanalizing treatment strategies |